Histrelin | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | |
Histrelin | hsa00220 | Arginine biosynthesis | 1.21E-02 | 1 | P15104 | GLUL | More | |
Histrelin | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | |
Histrelin | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Histrelin | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | |
Histrelin | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | |
Histrelin | hsa01100 | Metabolic pathways | 4.11E-02 | 7 | P30041, P20839, P08237, Q86XP1, Q9UHK6, Q86VZ5, Q9NVH6 | PRDX6, IMPDH1, PFKM, DGKH, AMACR, SGMS1, TMLHE | More | |
Histrelin | hsa01200 | Carbon metabolism | 4.06E-02 | 5 | P37837, O14521, P50213, P60891, Q02252 | TALDO1, SDHD, IDH3A, PRPS1, ALDH6A1 | More | |
Histrelin | hsa01230 | Biosynthesis of amino acids | 5.53E-03 | 2 | P15104, P37837 | GLUL, TALDO1 | More | |
Histrelin | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | |
Histrelin | hsa03013 | RNA transport | 4.73E-02 | 9 | P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, TACC3 | More | |
Histrelin | hsa04080 | Neuroactive ligand-receptor interaction | 4.15E-02 | 2 | Q01726, P41968 | MC1R, MC3R | More | |
Histrelin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Histrelin | hsa04142 | Lysosome | 2.64E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | |
Histrelin | hsa04145 | Phagosome | 3.11E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | |
Histrelin | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
Histrelin | hsa04330 | Notch signaling pathway | 7.49E-03 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | |
Histrelin | hsa04613 | Neutrophil extracellular trap formation | 9.53E-03 | 13 | P17252, O60603, P08246, Q9UM07, Q92769, Q6FI13, P14598, Q15080, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, ELA2, PADI4, HDAC2, H2AC18; H2AC19, NCF1, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Histrelin | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Histrelin | hsa04912 | GnRH signaling pathway | 3.39E-02 | 4 | P17252, Q16539, Q9Y6R4, Q14643 | PRKCA, MAPK14, MAP3K4, ITPR1 | More | |
Histrelin | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | |
Histrelin | hsa04919 | Thyroid hormone signaling pathway | 3.71E-02 | 2 | P26678, P08237 | PLN, PFKM | More | |
Histrelin | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
Histrelin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Histrelin | hsa04972 | Pancreatic secretion | 3.86E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | |
Histrelin | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | |
Histrelin | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Histrelin | hsa05152 | Tuberculosis | 4.16E-02 | 2 | Q99437, P25774 | ATP6V0B, CTSS | More | |
Histrelin | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Histrelin | hsa05222 | Small cell lung cancer | 4.26E-02 | 6 | P10826, Q13489, P10415, Q13077, O00463, P24522 | RARB, BIRC3, BCL2, TRAF1, TRAF5, GADD45A | More | |
Histrelin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Histrelin | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Histrelin | hsa05415 | Diabetic cardiomyopathy | 3.19E-02 | 7 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P14780 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, MMP9 | More | |